Deep Brain Stimulation Probes New Frontiers

Deep brain stimulation (DBS) currently comprises only about a quarter of the worldwide neuromodulation device market, but growth in this segment is strong. Both large and small competitors have targeted DBS, which has the potential to address a number of highly prevalent and underserved diseases and disorders.

Deep brain stimulation (DBS) devices, on the market for 20 years, have enabled the successful treatment of more than 100,000 patients worldwide with debilitating and increasingly prevalent neurological disorders such as Parkinson's disease (PD), essential tremor, dystonia, and epilepsy. But despite two decades of clinical and real-world experience, the full potential of the "brain pacemaker" market is just beginning to emerge, thanks to aggressive research and development efforts by the big players in this space. Over the past few months, new long-term data have been released that will help fuel growth in this market as two cardiac and neurotechnology device giants – St. Jude Medical Inc. and Boston Scientific Corp. – prepare to challenge worldwide neuromodulation leader Medtronic PLC with competitive, next-generation DBS systems. (Also see Also see "Neuromodulation Market: Innovation Brings High-Growth Rewards" - Medtech Insight, 27 March, 2013. and Also see "Emerging Peripheral Nerve Technologies Draw New Competitors To Neuromodulation Market" - Medtech Insight, 26 April, 2013.).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

New Guidance From Canada’s HTA Agency On Submission Of AI-Driven Evidence

 

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.

No FDA Reorg Planned, Makary Says

 
• By 

FDA Commissioner Marty Makary stated in a new interview that there will be no significant reorganization of the agency, despite earlier reports. Using his “guiding principles” of common sense and gold-standard science, he plans to focus on reforms including improved pathways for medical AI and food safety as well as addressing employee morale.